Translational Approaches in Biopharmaceutical Development

Abstract

Biopharmaceutical development--encompassing monoclonal antibodies, antibody-drug conjugates, bispecific antibodies,
gene therapies, cell therapies, and RNA therapeutics--has transformed oncology, autoimmunity, and rare disease
treatment over the past three decades, yet the translational gap between promising preclinical candidate and successful
clinical drug remains the most formidable challenge in the field, with first-in-human to approval success rates of 11.5%
overall and as low as 5.1% for oncology biologics. This review systematically analyses the translational bottlenecks at
each stage of the biopharmaceutical development pipeline--from target validation and lead molecule selection, through
preclinical pharmacology and toxicology, first-in-human dose selection, Phase I biomarker strategy, and late-stage
adaptive trial design--and evaluates the evidence base for emerging strategies that are improving translational success
rates. Key advances reviewed include: patient-derived organoid (PDO) and microphysiological system (MPS) platforms
that bridge the rodent-human species gap in pharmacology prediction; quantitative systems pharmacology (QSP)
modelling for human PK/PD extrapolation and clinical dose optimisation; companion diagnostic co-development
strategies that enrich trial populations for responders; adaptive Bayesian phase II/III seamless trial designs that
accelerate proof-of-concept decision-making; and the evolving regulatory science framework for accelerated approval
pathways (Breakthrough Therapy, PRIME) that have compressed median approval timelines by 3.2 years relative to
standard review. Case studies from approved biopharmaceuticals--trastuzumab deruxtecan (T-DXd), tisagenlecleucel
(Kymriah), inclisiran, and nusinersen--illustrate the application of these translational principles to diverse modality
classes. The review concludes by identifying artificial intelligence integration, digital biomarkers, and decentralised
clinical trial models as the three highest-impact emerging translational enablers.